Screener
CG Oncology CGON CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from sales and maturities of investments | 479,755 | 370,520 |
| Purchases of investments | (783,400) | (529,852) |
| Issuance of note receivable | — | (26,000) |
| Purchases of property and equipment | (772) | (30) |
| Net cash used in investing activities | (304,417) | (185,362) |
| Financing Activities | ||
| Proceeds from follow-on public offerings, net of issuance costs | 391,550 | — |
| Proceeds from exercise of common stock options | 3,750 | 701 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's capex?
- CG Oncology (CGON) reported capex of $468K in Q2 2026.
- How has CG Oncology's capex changed year-over-year?
- CG Oncology's capex increased by 3242.9% year-over-year, from $14K to $468K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about CG Oncology's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude